Implementation And Efficacy Of Stellest Spectacle Lenses For Myopia Control: Clinical Cases From Armenia

The escalating global prevalence of myopia underscores the urgency for effective control measures in ophthalmology. Stellest spectacle lenses, leveraging H.A.L.T. technology, represent a promising avenue for myopia management. This study aims to evaluate the implementation and efficacy of Stellest lenses in controlling myopia progression, with a focus on clinical cases from Armenia.

The study was conducted in Armenia, where over 300 Stellest lenses have been prescribed for myopia control.

We conducted a retrospective analysis of clinical cases involving Stellest lenses over a two-year period. Autorefractor results were monitored, with only four patients exhibiting changes post-prescription.

Among the cases, a notable instance involved a family with three children aged 13, 15, and 18. Stellest lenses were prescribed for the 13 and 15-year-olds, while the 18-year-old received regular monofocal glasses due to the belief that myopia stabilizes around that age. However, subsequent 3 month follow-up revealed a progression of -0.25 in one eye and -0.5 diopters in the other eye of the 18-year-old, prompting an immediate switch to Stellest lenses. Further monitoring over six months indicated a halt in myopia progression in this case.

The findings underscore the effectiveness of Stellest lenses in controlling myopia progression, as evidenced by clinical cases in Armenia. Early intervention with Stellest lenses may offer significant benefits in managing myopia, even in cases where progression is expected to stabilize. This highlights the importance of proactive measures in addressing the global burden of myopia